Verrica Pharmaceuticals Inc. Common Stock
VRCA Real Time Price USDRecent trades of VRCA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by VRCA's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Applicator Jul. 23, 2024
-
Patent Title: Ampule crush tool Apr. 11, 2023
-
Patent Title: Quantification and preparation of pharmaceutical grade cantharidin Nov. 09, 2021
-
Patent Title: Treatment of cutaneous disorders Oct. 19, 2021
-
Patent Title: Compositions, methods and systems for the treatment of cutaneous disorders Jul. 06, 2021
-
Patent Title: Applicator Oct. 27, 2020
-
Patent Title: Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives Aug. 18, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of VRCA in WallStreetBets Daily Discussion
Recent insights relating to VRCA
Recent picks made for VRCA stock on CNBC
ETFs with the largest estimated holdings in VRCA
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view VRCA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.